The next two discretionary priority vouchers to be awarded by the FDA are reported to be heading for two MSD candidates with blockbuster potential. According to Reuters, MSD – known as Merck & Co in ...
Nearly two years after Takeda pulled its US marketing application for a vaccine against dengue fever, MSD has advanced a rival shot into phase 3. The international MOBILIZE-1 trial is looking at a ...
Honda now joins the sweep of rebrands with a logo that wouldn’t look out of place on the outside of a spaceship or worn as a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback